Articles related to LUNG CANCER

This phase 2 trial demonstrated that tarlatamab showed antitumor activity with durable objective responses and promising survival outcomes in patients with previously treated small-cell lung cancer. With a manageable safety profile and no new safety signals identified, tarlatamab could represent a significant advancement in the treatment landscape for these patients.

Explore how high-dose hyperfractionated thoracic radiotherapy is setting new standards in LS-SCLC treatment.

Don’t miss this crucial update on how biomarker-guided first-line treatment can substantially improve survival rates in advanced NSCLC patients.

Takeda’s decision to withdraw Exkivity from the US market raises questions about treatment alternatives for NSCLC patients with specific EGFR mutations; stay updated on this evolving situation.

New research indicates that PCI offers significant survival advantages over TRT in treating extensive-stage small cell lung cancer, challenging existing treatment protocols.

Recent findings from the MARS 2 trial challenge traditional treatment protocols for mesothelioma, indicating that chemotherapy alone may offer improved outcomes over combined surgical approaches. Discover why experts are re-evaluating long-standing surgical treatments.